Zydus Lifesciences Limited
ZYDUSLIFE
Pozycja w akcjach
#1755
Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952,... Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952, operates globally in the pharmaceutical and consumer goods sectors. Renamed from Cadila Healthcare Limited in February 2022, the company manages the entire lifecycle of pharmaceutical products, from research and development to manufacturing, marketing, and distribution. Its extensive reach covers India, the United States, Europe, Latin America, the Asia Pacific region, and Africa. The company's pharmaceutical division provides a broad spectrum of offerings, including finished dosage human formulations (such as generics, branded generics, and specialized treatments like biosimilars and vaccines), as well as active pharmaceutical ingredients (APIs). Zydus focuses on therapeutic areas like pain management, neurology, dermatology, and liver diseases, among others. Additionally, it is developing a pipeline of biological products aimed at conditions such as oncology, autoimmune disorders, nephrology, ophthalmology, inflammation, rheumatology, hepatology, and infectious diseases. In its consumer products segment, Zydus offers popular wellness brands including Complan, the EverYuth range of skincare products, Nycil, Glucon-D glucose powder, Nutralite, and the Nutralite Doodhshakti dairy product line. Beyond these core operations, the company is also involved in investment activities, animal health and veterinary services, pharmacy retail, and human resource supply and administration.
Cena akcji
$12.29
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$12.26B
Zmiana (1 dzień)
-1.01%
Zmiana (1 rok)
7.78%
Kraj
IN
Handel Zydus Lifesciences Limited (ZYDUSLIFE)
Kategoria
Healthcare
EPS dla Zydus Lifesciences Limited (ZYDUSLIFE)
EPS na dzień June 2026 TTM: $0.50
Według najnowszych raportów finansowych i ceny akcji firmy Zydus Lifesciences Limited, obecny EPS (TTM) wynosi $0.50. Na koniec roku 2024 firma miała EPS w wysokości $0.45, wzrost w porównaniu do do EPS z roku 2023, który wynosił $0.24.
Historia EPS dla Zydus Lifesciences Limited od 2004 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $0.50 | -6.57% |
| 2025 | $0.53 | 15.66% |
| 2024 | $0.45 | 93.04% |
| 2023 | $0.24 | -18.37% |
| 2022 | $0.29 | -1.80% |
| 2021 | $0.29 | 92.66% |
| 2020 | $0.15 | -41.37% |
| 2019 | $0.26 | -3.38% |
| 2018 | $0.27 | 19.91% |
| 2017 | $0.22 | -21.26% |
| 2016 | $0.29 | 58.30% |
| 2015 | $0.18 | 37.48% |
| 2014 | $0.13 | 11.58% |
| 2013 | $0.12 | -6.53% |
| 2012 | $0.13 | -19.49% |
| 2011 | $0.16 | 112.82% |
| 2010 | $0.07 | 16.35% |
| 2009 | $0.06 | -7.62% |
| 2008 | $0.07 | 19.23% |
| 2007 | $0.06 | -98.42% |
| 2006 | $3.63 | 6,117.81% |
| 2005 | $0.06 | -10.43% |
| 2004 | $0.07 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | 12.34% |
IN
|
